Income Statement Presentation 2023
2022: Good Group results
Group sales +2% driven by good performance in both divisions
•
.
•
Pharma portfolio rejuvenation ongoing, key products offsetting LOE impact
Diagnostics with good growth momentum driven by strong base business (+7%)
Decline of roughly CHF 1 bn in COVID-19 sales
Profit and Cash Flow
•
Core EPS growth +5%, Operating Free Cash Flow remains strong (CHF 17.7bn)
Roche
Growth supported by key products and strong launches
•
.
•
Pharma key products Ocrevus, Hemlibra, Vabysmo, Evrysdi, Tecentriq, Phesgo and Polivy continuing to grow strongly
Key approvals achieved: Vabysmo in nAMD/DME in US/EU; Polivy in 1L DLBCL in EU/Japan/China; Tecentriq in adjuvant NSCLC in EU;
Lunsumio in 3L+FL in US/EU
Launches of next generation of SARS-CoV-2 rapid antigen test 2.0, cobas® HCV DUO, Elecsys® pTau/AB42 ratio Gen2 CSF (FDA).
Benchmark Ultraplus, Digital LightCyler, cobasⓇ pure and 5800 (FDA)
Significant newsflow in 2023
•
•
Pharma: 16 late-stage read-outs incl. 3 NMEs (tiragolumab, crovalimab, SRP-9001) and important line extensions for Tecentriq,
Venclexta, Alecensa, Ocrevus, Lunsumio and TNKase; positive results for Tecentriq in adjuvant HCC and Susvimo in DME/DR achieved
Diagnostics: CCM Vertical, LightCycler Pro, Anti-HEV IgG/IgM, HBeAg Quant, IL-6 Neonatal sepsis
Growth rates at CER (Constant exchange Rates); LOE-loss-of-exclusivity
6View entire presentation